Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Acupuncture · 1 trial · 1 indication
Ten items addressing physical functioning which are part of a short-form health survey with 36 questions. Scores range between 0 and 100 with higher scores indicating better function.
| Arm | Type | Description |
|---|---|---|
| Bi-weekly acupuncture treatment | EXPERIMENTAL | Bi-weekly acupuncture treatment |
| Wait list | ACTIVE_COMPARATOR | Wait list for 2 months followed by weekly acupuncture for 4 months |
| Name | Type | Description |
|---|---|---|
| Acupuncture | DEVICE | Sterile insertive needles are applied by licensed, experienced practitioners. |
Inclusion 1. deployed to the "Gulf Theater of operations, as defined by 38 CFR 3.317, includes Iraq, Kuwait, Saudi Arabia, Bahrain, Qatar, the United Arab Emirates, Oman, the Gulf of Aden, the Gulf of Oman, the Persian Gulf, the Arabian Sea, the Red Sea, and the airspace above all of these location...
Acupuncture is being studied as a treatment for Persian Gulf Syndrome, also known as Gulf War Illness. It is an investigational therapy in clinical development, currently in Phase 1 trials. The treatment involves the traditional practice of inserting thin needles into specific points on the body to potentially alleviate symptoms associated with this condition.
Acupuncture is being developed by United Therapeutics Corporation, a biotechnology company traded on the NASDAQ under the ticker symbol UTHR. The company is conducting clinical research to evaluate the safety and efficacy of acupuncture as a potential treatment for Persian Gulf Syndrome.
Acupuncture is currently in Phase 1 clinical development for Persian Gulf Syndrome. It is an investigational therapy, meaning it has not yet been approved by regulatory authorities. The Phase 1 trial has been completed, and the therapy is still undergoing clinical evaluation to determine its safety and potential effectiveness.
Acupuncture has one completed clinical trial registered under NCT01305811, titled 'Acupuncture in the Treatment of Gulf War Illness.' This Phase 1 study enrolled 104 participants with Persian Gulf Syndrome in the United States. The trial was randomized, double-blind, and active-controlled, with participants aged 39 years and older.
Acupuncture is a distinct therapeutic approach being investigated for Persian Gulf Syndrome. It is not known to be the same as any other drug or treatment. The therapy is being evaluated on its own merits in clinical trials, and no alternative names have been associated with this specific investigational use.